Enzolytics Inc (ENZC)

[Jeff Taitano]

IMMB BG is a Subsidiary of IMMB which was the parent company who had the Exclusive License Agreement. Harry the majority owner of IMMB.

IMMB BG has a Sub-license agreement with Immunotech (which is now transferred to ENZC) and is how Harry is able to go after all of the clinical trials data from IMMB BG in Sofia which was transferred through the asset purchase agreement.

ENZC "paid" common stock to Immunotech and paid off debts owed by Immunotech according to the Annual Filing

On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by Enzolytics, Inc.

Additionally, Dimitar is shown as receiving 170,000,000 common restricted shares on March 23, 2018 - as well as a list of other people likely associated with the IMMB BG subsidiary that have a number of shares being received around the same time in March of 2018. All of their names appear to be Bulgarian.



You're quoting a website that Dimitar can edit at will, and who obviously is bitter at the deal. He is just trying to be a thorn in Harrys side so he can get a better deal.

Also, have you seen Dimitars LinkedIn or Twitter?